Your browser doesn't support javascript.
loading
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.
Castellsagué, Xavier; Naud, Paulo; Chow, Song-Nan; Wheeler, Cosette M; Germar, Maria Julieta V; Lehtinen, Matti; Paavonen, Jorma; Jaisamrarn, Unnop; Garland, Suzanne M; Salmerón, Jorge; Apter, Dan; Kitchener, Henry; Teixeira, Julio C; Skinner, S Rachel; Limson, Genara; Szarewski, Anne; Romanowski, Barbara; Aoki, Fred Y; Schwarz, Tino F; Poppe, Willy A J; Bosch, F Xavier; de Carvalho, Newton S; Peters, Klaus; Tjalma, Wiebren A A; Safaeian, Mahboobeh; Raillard, Alice; Descamps, Dominique; Struyf, Frank; Dubin, Gary; Rosillon, Dominique; Baril, Laurence.
  • Castellsagué X; Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia, IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Naud P; Department of Gynecology and Obstetrics, Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil.
  • Chow SN; Department of Obstetrics and Gynecology, College of Medicine and the Hospital, National Taiwan University, Taipei, Taiwan.
  • Wheeler CM; Department of Pathology and Department of Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque.
  • Germar MJ; Department of Obstetrics and Gynaecology, University of the Philippines College of Medicine, Philippine General Hospital, Manila, The Philippines.
  • Lehtinen M; University of Tampere, School of Public Health, Tampere.
  • Paavonen J; Department of Obstetrics and Gynaecology, University of Helsinki, Finland.
  • Jaisamrarn U; Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Garland SM; Department of Microbiology and Infectious Diseases, The Royal Women's Hospital Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Childrens Research Institute Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.
  • Salmerón J; Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, Mexico.
  • Apter D; Family Federation of Finland, Sexual Health Clinic, Helsinki, Finland.
  • Kitchener H; Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, United Kingdom.
  • Teixeira JC; Departamento de Tocoginecologia da Unicamp, University of Campinas, Sao Paulo, Brazil.
  • Skinner SR; Vaccines Trials Group, Telethon Institute for Child Health Research, Perth, Western Australia Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, New South Wales, Australia.
  • Limson G; College of Medicine, University of the Philippines, Philippine General Hospital, Makati Medical Centre, Makati City, The Philippines.
  • Szarewski A; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, United Kingdom.
  • Romanowski B; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
  • Aoki FY; Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
  • Schwarz TF; Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Germany.
  • Poppe WA; Department of Gynaecology, University Hospital KU Leuven Gasthuisberg, Belgium.
  • Bosch FX; Unit of Infections and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia, IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain Network on Cooperative Cancer Research, RTICC, Catalonia, Spain.
  • de Carvalho NS; Department of Gynecology and Obstetrics, Federal University of Paraná, Infectious Diseases in Gynecology and Obstetrics Sector, Curitiba, Brazil.
  • Peters K; Facharzt für Frauenheilkunde und Geburtshilfe, Hamburg, Germany.
  • Tjalma WA; Multidisciplinary Breast Clinic-Gynecologic Oncology, Antwerp University Hospital, University of Antwerp, Belgium.
  • Safaeian M; Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, Rockville, Maryland.
  • Raillard A; 4Clinics, Paris, France.
  • Descamps D; GlaxoSmithKline Vaccines, Wavre, Belgium.
  • Struyf F; GlaxoSmithKline Vaccines, Wavre, Belgium.
  • Dubin G; GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania.
  • Rosillon D; GlaxoSmithKline Vaccines, Wavre, Belgium.
  • Baril L; GlaxoSmithKline Vaccines, Wavre, Belgium.
J Infect Dis ; 210(4): 517-34, 2014 Aug 15.
Article en En | MEDLINE | ID: mdl-24610876
BACKGROUND: We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681). METHODS: Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]). RESULTS: High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection, atypical squamous cells of undetermined significance or greater (ASCUS+), and cervical intraepithelial neoplasia grades 1/2 or greater (CIN1+, CIN2+). For HPV-18, although seropositivity was associated with lower risk of ASCUS+ and CIN1+, no association between naturally acquired antibodies and infection was demonstrated. Naturally acquired HPV-16 antibody levels of 371 (95% confidence interval [CI], 242-794), 204 (95% CI, 129-480), and 480 (95% CI, 250-5756) EU/mL were associated with 90% reduction of incident infection, 6-month persistent infection, and ASCUS+, respectively. CONCLUSIONS: Naturally acquired antibodies to HPV-16, and to a lesser extent HPV-18, are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Papillomaviridae / Infecciones por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Papillomaviridae / Infecciones por Papillomavirus / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans Idioma: En Año: 2014 Tipo del documento: Article